Skip Navigation

This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Blakemore, W. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blakemore, W. F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 123, No. 8, 1543-1544, August 2000
© 2000 Oxford University Press


Editorial

Olfactory glia and CNS repair: a step in the road from proof of principle to clinical application

William F. Blakemore

Department of Clinical Veterinary Medicine, Cambridge University, Cambridge, UK

Considerable advances have been made in the last decade in devising and evaluating cell transplantation strategies for enhancing axon regeneration for patients with spinal cord trauma, and in achieving remyelination in chronic demyelinating diseases such as multiple sclerosis. Thus, a number of studies have established that transplantation of glial cells can have beneficial consequences in experimental models of spinal cord trauma and demyelination. In particular, in rats, it has been shown that implantation of Schwann cells or olfactory glial cells results in significant regeneration of axons across spinal cord transection sites and that this is associated with an improvement of locomotor function (Cheng et al., 1997Go; Xu et al., 1999Go; Ramón-Cueto et al., 2000Go). A potential therapeutic superiority of olfactory glia over Schwann cells was demonstrated by experiments in which the number of regenerating axons crossing a transection site was dramatically increased when olfactory glia were placed at the interface between a Schwann-cell-filled guidance tube and the damaged spinal cord (Ramón-Cueto et al., 1998Go). The reports of such experiments stimulate considerable media interest and, not unexpectedly, raise patient hopes for a cure to their disability. There is therefore a major challenge for neuroscientists and clinicians to build on the proof of the principle established by these experimental studies with a view to adapting the approach for clinical use.

In any situation where cell therapy is being considered, a number of practical issues have to be addressed before any clinical trial can be contemplated. One of the most fundamental of these issues is whether the required cells can be obtained from the patient themselves, since this would avoid the necessity for immunosuppression. With Schwann cells this issue has largely been resolved. It is possible to expand human Schwann cells from small amounts of starting material, using a combination of heregulin and forskolin, and to drive cell multiplication to a point where sufficient cells could be available for use in a patient. The article by Barnett and colleagues in this issue of Brain demonstrates that the same can now be achieved for olfactory glia (Barnett et al., 2000Go). This paper represents the first report of the in vitro cultivation and expansion of human olfactory glial cells. An animal model of persistent demyelination is then used to establish that in vitro expansion has not led to loss of function or uncontrolled cell proliferation. This study thus represents a significant advance for those considering olfactory glia as a potential cell type to use in clinical trials aimed at enhancing regeneration of axons following spinal cord trauma.

This paper also highlights another important point for those trying to make the transition from a proof of principle established using rodents to the use of the approach in man, because it demonstrates once again that the cultivation and expansion of human cells is not as straightforward as expansion of their rodent counterparts. Thus, while rodent olfactory glia can be selected through their expression of antigens recognized by the O4 monoclonal antibody, human cells do not express this antigen. Instead, use had to be made of another marker for this cell type, the low affinity NGFr. However, in contrast to rodent cells this receptor is downregulated during culture, making identification, and thus further selection of olfactory glia difficult, should this be required prior to therapeutic use. Such observations indicate that new reagents and techniques have to be developed by those who need to work with human cells. This imposes considerable difficulties for the researcher, since obtaining regular supplies of human cells required to test and evaluate culture methods and reagents is less straightforward than is the case with rodent tissue, making progress slow. A further constraint to making the rodent–human transition is that the development work required is often perceived as unattractive scientifically because progress is slow. Moreover, the work is also often perceived as lacking the novelty so essential if work is to be published in high-ranking journals, a prerequisite for survival in these competitive days. Therefore, it is important that journals such as Brain take a special interest in the studies that are required to take proof of principle established in experimental rodent models through to their clinical application.

References

Barnett SC, Alexander CL, Iwashita Y, Gilson JM, Crowther J, Clark L, et al. Identification of a human olfactory ensheathing cell that can effect transplant-mediated remyelination of demyelinated CNS axons. Brain 2000; 123: 1581–8.[Abstract/Free Full Text]

Cheng HR, Almström S, Giménez-Llort L Chang R, Ove Ogren S, Hoffer B, et al. Gait analysis of adult paraplegic rats after spinal cord repair. Expt Neurol 1997; 148: 544–57.[Medline]

Ramón-Cueto A, Plant GW, Avila J, Bunge MB. Long-distance axonal regeneration in the transected adult rat spinal cord is promoted by olfactory ensheathing glia transplants. J Neurosci 1998; 18: 3803–15.[Abstract/Free Full Text]

Ramón-Cueto A, Cordero MI, Santos-Benito FF, Avila J. Functional recovery of paraplegic rats and motor axon regeneration in their spinal cords by olfactory ensheathing glia. Neuron 2000; 25: 425–35.[Web of Science][Medline]

Xu XM, Zhang SX, Li H, Aebischer P, Bunge MB. Regrowth of axons into the distal spinal cord through a Schwann-cell-seeded mini-channel implanted into hemisected adult rat spinal cord. Eur J Neurosci 1999; 11: 1723–40.[Medline]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Arch NeurolHome page
A. G. Rabchevsky and G. M. Smith
Therapeutic Interventions Following Mammalian Spinal Cord Injury
Arch Neurol, May 1, 2001; 58(5): 721 - 726.
[Full Text] [PDF]


This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Blakemore, W. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blakemore, W. F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?